Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Published:2019-06 Issue:6 Volume:17 Page:721-749
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Tallman Martin S.¹,Wang Eunice S.²,Altman Jessica K.³,Appelbaum Frederick R.⁴,Bhatt Vijaya Raj⁵,Bixby Dale⁶,Coutre Steven E.⁷,De Lima Marcos⁸,Fathi Amir T.⁹,Fiorella Melanie¹⁰,Foran James M.¹¹,Hall Aric C.¹²,Jacoby Meagan¹³,Lancet Jeffrey¹⁴,LeBlanc Thomas W.¹⁵,Mannis Gabriel⁷,Marcucci Guido¹⁶,Martin Michael G.¹⁷,Mims Alice¹⁸,O’Donnell Margaret R.¹⁶,Olin Rebecca¹⁹,Peker Deniz²⁰,Perl Alexander²¹,Pollyea Daniel A.²²,Pratz Keith²³,Prebet Thomas²⁴,Ravandi Farhad²⁵,Shami Paul J.²⁶,Stone Richard M.²⁷,Strickland Stephen A.²⁸,Wieduwilt Matthew¹⁰,Gregory Kristina M.,Hammond Lydia²⁹,Ogba Ndiya²⁹,

Affiliation:

1. 1Memorial Sloan Kettering Cancer Center;

2. 2Roswell Park Comprehensive Cancer Center;

3. 3Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

4. 4Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

5. 5Fred & Pamela Buffett Cancer Center;

6. 6University of Michigan Rogel Cancer Center;

7. 7Stanford Cancer Institute;

8. 8Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

9. 9Massachusetts General Hospital Cancer Center;

10. 10UC San Diego Moores Cancer Center;

11. 11Mayo Clinic Cancer Center;

12. 12University of Wisconsin Carbone Cancer Center;

13. 13Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

14. 14Moffitt Cancer Center;

15. 15Duke Cancer Institute;

16. 16City of Hope National Medical Center;

17. 17St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

18. 18The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

19. 19UCSF Helen Diller Family Comprehensive Cancer Center;

20. 20O’Neal Comprehensive Cancer Center at UAB;

21. 21Abramson Cancer Center at the University of Pennsylvania;

22. 22University of Colorado Cancer Center;

23. 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

24. 24Yale Cancer Center/Smilow Cancer Hospital;

25. 25The University of Texas MD Anderson Cancer Center;

26. 26Huntsman Cancer Institute at the University of Utah;

27. 27Dana-Farber/Brigham and Women’s Cancer Center;

28. 28Vanderbilt-Ingram Cancer Center; and

29. 29National Comprehensive Cancer Network

Abstract

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 345 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches to anticancer therapy based on modulation of DNA methylation;Siberian journal of oncology;2024-09-09

2. Chimeric antigen receptor T-cell therapy in acute myeloid leukaemia: Novel therapeutic approaches to longstanding challenges;Gene Reports;2024-09

3. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy;Critical Reviews in Oncology/Hematology;2024-09

4. Lipopolymer/siRNA Complexes Engineered for Optimal Molecular and Functional Response with Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia;Acta Biomaterialia;2024-09

5. WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia;British Journal of Haematology;2024-08-27